- Global Pharma News & Resources

KARMET Study Begins Enrollment

KARMET Study Begins Enrollment

PR Newswire

PHILADELPHIA, Jan. 9, 2019

PHILADELPHIA, Jan. 9, 2019 /PRNewswire/ -- Enterin Inc., a privately held CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, began screening patients for the KARMET study. Dr. Goldstein of Atlantis, Florida, and Dr. Kadimi of Fairfield, Connecticut, have both enrolled. The study is a Phase 2b multicenter, randomized, double-blind, placebo-controlled, multiple-dose study to evaluate safety, tolerability and efficacy of orally administered ENT-01 for the treatment of Parkinson's disease. This clinical trial will enroll 72 patients over a six-month period. Details relating to the study can be found at (NCT#03781791) and contact information is available on the Enterin website.

The study is a follow-up to a successful Phase 2a study (the RASMET study) completed last year. ENT-01 is an orally administered, synthetic derivative of squalamine that acts locally on the enteric nerve cells of the gut, stimulating gut motility and altering afferent neural signaling from gut to brain. Based on results from the RASMET study,  ENT-01 has the potential to ameliorate some or all of the non-motor and motor symptoms of Parkinson's disease, including constipation, motor dysfunction, hallucinations, memory, depression, fragmented sleep and REM-behavior disorder.

About Enterin Inc.

Enterin Inc. is the first company to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. In the gut, this results in improved motility. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the constipation and neurologic symptoms of Parkinson's disease.

For more information, please visit

Enterin Inc.

View original content to download multimedia:

SOURCE Enterin Inc.

Editor Details

Last Updated: 09-Jan-2019